H1 2024 Oncolytic Viruses Landscape Review

Explore the dynamic and evolving world of oncolytic virotherapies with our exclusive H1 2024 Oncolytic Viruses Landscape Review Series. This two-part series, derived from Beacon’s extensive database as of July 1st, 2024, provides unparalleled visibility into the oncolytic viruses landscape. Whether you’re tracking the latest drug developments, clinical trials, or emerging trends, this series equips you with in-depth data to help you navigate the fast-changing field of oncolytic viruses.

Download Here

Part 1: Drug and Trial Landscape Review

Get an in-depth look at the oncolytic virus landscape with our analysis of drug development and clinical trials. Covering 658 assets, this section highlights the virus families, genetic modifications, trial statuses, and regulatory updates that defined the first half of 2024. Discover key trends in preclinical research and learn about the latest challenges in advancing virotherapies to late-stage trials.

Download Here

Part 2: Deal and Market Insights Summary

Part 2 of the H1 2024 Oncolytic Viruses Landscape Review Series shifts the focus to the commercial side, offering a comprehensive overview of the deal landscape, financing trends, and company profiles. The oncolytic virus market continues to show positive momentum, with a growing number of deals each year. This section covers the top deals of 2024, as well as insights into company distribution and the total funding raised to date. A forward-looking analysis focuses on the picornaviridae family and combination trials, offering a glimpse into the future opportunities within the oncolytic virus space.

Coming Soon

About the H1 2024 Landscape Review

Part 1: In-depth analysis of the drug and trial landscapes, including regulatory updates, genetic modifications, and detailed status of the most promising assets.
Part 2: Detailed overview of the deal landscape, company insights, and funding trends, giving you a complete commercial view of the market.

Why Choose Beacon’s Oncolytic Viruses Review? Beacon’s unrivaled depth of preclinical data and ontologies provides insights you won’t find anywhere else. Gain full visibility into the trends shaping the future of oncolytic viruses with comprehensive data across all therapeutic classes and technologies.

Stay ahead in the rapidly advancing field of oncolytic virotherapies with this essential resource. Download your copy today and unlock exclusive insights that will drive your strategic decisions in 2024 and beyond.

Find out more

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.

Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.

With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.

Discover a database tailored to your needs